Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience.
10.3346/jkms.2008.23.5.819
- Author:
Yong Pil CHONG
1
;
Shin KIM
;
Ok Bae KO
;
Ja Eun KOO
;
Danbi LEE
;
Sang Hyoung PARK
;
Soo Jung PARK
;
Daeho LEE
;
Sang We KIM
;
Cheolwon SUH
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. csuh@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Multiple Myeloma;
Immunoglobulin D;
Stem Cell Transplantation;
Prognosis
- MeSH:
Adult;
Aged;
Female;
Humans;
Immunoglobulin D/*chemistry;
Male;
Melphalan/*pharmacology;
Middle Aged;
Multiple Myeloma/*drug therapy/genetics/*immunology;
Myeloablative Agonists/*pharmacology;
Prognosis;
Retrospective Studies;
Stem Cell Transplantation/*methods;
Transplantation, Autologous;
Treatment Outcome
- From:Journal of Korean Medical Science
2008;23(5):819-824
- CountryRepublic of Korea
- Language:English
-
Abstract:
Immunoglobulin (Ig) D multiple myeloma (MM) accounts for 2% of all MM cases and has been reported to be associated with poor prognosis compared with other MM subtypes. The aim of the present study was to compare the effects of high-dose melphalan treatment and autologous stem cell transplantation (ASCT) on the survival of patients with IgD MM and patients with other MM subtypes. Between November 1998 and January 2005, a total of 77 patients with MM who underwent ASCT at the Asan Medical Center were enrolled in this study. High-dose melphalan (total 200 mg/m2) was used as high-dose chemotherapy. The study population was divided into two groups based on MM subtype: those with IgD MM; and those with other MM subtypes. A total of 8 patients with IgD MM were identified, accounting for about 10% of the study population. Thirty-six patients (47%) had IgG MM, 17 patients (22%) had IgA MM, and 16 patients (20%) had free light-chain MM. The two groups were similar in baseline characteristics. The median follow-up was 17 months and the median overall survival (OS) was 39 months. In the IgD MM group, median eventfree survival (EFS) and OS were 6.9 and 12 months, respectively. In the patients with other MM subtypes, median EFS and OS were 11.5 and 55.5 months (p=0.01, p<0.01), respectively. Multivariate analysis of all patients identified IgD subtype (p=0.002) and Southwest Oncology Group (SWOG) stage 2 or greater at the time of ASCT (p=0.01) as adverse prognostic factors for survival. In this small study at a single center in Korea, patients with IgD MM had poorer outcomes after ASCT than did patients with other MM subtypes.
